- In April 2024, Johnson & Johnson MedTech expanded its SURGICEL hemostatic product line across India and Southeast Asia, aiming to meet the growing demand for advanced intraoperative bleeding control in high-volume public hospitals. This strategic move underscores the company's commitment to improving surgical outcomes in emerging healthcare markets by providing clinically validated, easy-to-use hemostatic agents suited for diverse surgical specialties
- In March 2024, Baxter International Inc. announced the launch of its next-generation FLOSEAL hemostatic matrix in China, designed to offer enhanced handling, faster hemostasis, and improved safety. This development reflects Baxter’s focus on delivering innovative solutions tailored for the increasing number of minimally invasive and complex surgeries being performed in Asia-Pacific, particularly in tertiary care centers
- In February 2024, B. Braun inaugurated a regional training and education center in Malaysia to support the adoption of its bio surgical agents among surgeons and healthcare professionals across the region. The center offers hands-on training modules for the application of hemostats and sealants, reflecting the company’s commitment to strengthening clinical expertise and improving surgical practices in Asia-Pacific
- In January 2024, CSL Behring formed a distribution partnership with a leading Japanese medical supply group to expand the reach of its fibrin sealant products in the country’s growing surgical market. This collaboration is aimed at addressing the increased need for biocompatible, plasma-derived agents in cardiovascular and neurosurgical applications
- In December 2023, CryoLife Inc. (now part of Artivion, Inc.) secured regulatory approval to market its surgical adhesives in South Korea and Singapore, marking a significant step in the company’s Asia-Pacific expansion strategy. These approvals allow CryoLife to offer high-performance surgical sealants to a wider range of hospitals and surgical centers, reinforcing its position in the regional bio surgical agents market
